Clinical Trial Update: Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PR013 topical ophthalmic drops versus vehicle for allergic conjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• PR013

Snippet

Sponsor: Realm Therapeutics, Inc. | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED